Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc R Theoret

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2017
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on IpilimumabMaitreyee Hazarika, Meredith K Chuk, Marc R Theoret, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I MutationGulsum E Pamuk, Edwin C Y Chow, Alexei C Ionan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2025
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian CancerMirat Shah, Ting-Yu Chen, Gwynn Ison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2020
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular CarcinomaSandra J Casak, Martha Donoghue, Lola Fashoyin-Aje, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2024
Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are BreastfeedingJorge E Cortes, Elisabetta Abruzzese, Elyce H Cardonick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2020
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
The Oncologist|July 1, 2021
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public HealthElaine Chang, Lorraine Pelosof, Steven Lemery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2020
Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case StudiesJamie R Brewer, Elaine Chang, Sundeep Agrawal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2022
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other RearrangementTimil H Patel, Leigh Marcus, M Naomi Horiba, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2017
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on IpilimumabMaitreyee Hazarika, Meredith K Chuk, Marc R Theoret, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2024
FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I MutationGulsum E Pamuk, Edwin C Y Chow, Alexei C Ionan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2025
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian CancerMirat Shah, Ting-Yu Chen, Gwynn Ison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2020
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular CarcinomaSandra J Casak, Martha Donoghue, Lola Fashoyin-Aje, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2024
Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are BreastfeedingJorge E Cortes, Elisabetta Abruzzese, Elyce H Cardonick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2020
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
The Oncologist|July 1, 2021
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public HealthElaine Chang, Lorraine Pelosof, Steven Lemery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2020
Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case StudiesJamie R Brewer, Elaine Chang, Sundeep Agrawal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2022
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other RearrangementTimil H Patel, Leigh Marcus, M Naomi Horiba, et al.
Pageof 11